Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors

BACKGROUND: Overexpression of syndecan-1 (CD138) in breast carcinoma correlates with a poor prognosis and an aggressive phenotype. The objective of this study was to evaluate the potential of targeting CD138 by immuno-PET imaging and radioimmunotherapy (RIT) using the antihuman syndecan-1 B-B4 mAb r...

Descripción completa

Detalles Bibliográficos
Autores principales: Rousseau, Caroline, Ruellan, Anne Lise, Bernardeau, Karine, Kraeber-Bodéré, Françoise, Gouard, Sebastien, Loussouarn, Delphine, Saï-Maurel, Catherine, Faivre-Chauvet, Alain, Wijdenes, John, Barbet, Jacques, Gaschet, Joëlle, Chérel, Michel, Davodeau, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250983/
https://www.ncbi.nlm.nih.gov/pubmed/22214534
http://dx.doi.org/10.1186/2191-219X-1-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250983/
https://www.ncbi.nlm.nih.gov/pubmed/22214534
http://dx.doi.org/10.1186/2191-219X-1-20

Ejemplares similares